Vertex Pharmaceuticals (VRTX) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue rose 3% year-over-year to $2.77 billion, driven by TRIKAFTA/KAFTRIO and strong launches of ALYFTREK and JOURNAVX, with continued CF franchise growth and global rollout of CASGEVY.

• ALYFTREK approved in U.S. and U.K. for CF ages 6+, showing strong uptake and label expansion; JOURNAVX launched as first oral non-opioid for acute pain in over 20 years, achieving over 20,000 prescriptions and broad payer coverage.

• CASGEVY, a gene-edited therapy for sickle cell disease and beta thalassemia, continued global rollout with over 65 treatment centers activated and ~90 patients initiating treatment, alongside expanding reimbursement.

• Pipeline progress included four pivotal programs in phase III and a fifth soon to start, spanning CF, pain, type 1 diabetes, and kidney diseases, with key data readouts and regulatory filings expected in 2025-2026.

• Raised 2025 revenue guidance to $11.85–$12 billion, reflecting robust product uptake, pipeline advancement, and new launches.

Financial highlights

• Q1 2025 total revenue was $2.77 billion, up from $2.69 billion in Q1 2024; U.S. revenue grew 9% while ex-U.S. declined 5% due to Russia IP issues.

• Q1 2025 non-GAAP operating income was $1.18 billion (43% margin), down from $1.34 billion in Q1 2024; GAAP operating income was $630.1 million.

• Net income was $646.3 million, down 41% from $1,099.6 million in Q1 2024, mainly due to a $379 million intangible asset impairment charge for VX-264.

• Non-GAAP EPS was $4.06, compared to $4.76 in Q1 2024; GAAP EPS was $2.49.

• Ended the quarter with $11.4 billion in cash and investments after $425 million in share repurchases.

Outlook and guidance

• 2025 total revenue guidance raised to $11.85–$12 billion, assuming continued CF growth, new launches, and Alpine Immune Sciences contribution in H2 2025.

• Combined non-GAAP R&D, IP R&D, and SG&A expense guidance unchanged at $4.9–$5 billion; GAAP guidance at $5.55–$5.7 billion.

• Non-GAAP effective tax rate expected at 20.5–21.5% for 2025.

• Guidance includes continued investment in pipeline, commercial ramp-up, and immaterial tariff impact.

• Anticipate European Commission approval for ALYFTREK in H2 2025 and ongoing regulatory submissions in multiple countries.